

PRIVILEGED AND CONFIDENTIAL
ATTORNEY-CLIENT COMMUNICATION
AMERICAN ACADEMY OF DERMATOLOGY
MARCH 10, 2025

Present

Seemal R. Desai, MD, FAAD, President
Cyndi J. Yag-Howard, MD, FAAD, Vice President
Terrence A. Cronin, Jr., MD, FAAD, Immediate Past President
Daniel D. Bennett, MD, FAAD, Secretary-Treasurer
Keyvan Nouri, MD, MBA, FAAD, Assistant Secretary-Treasurer
Susan C. Taylor, MD, FAAD, President-elect
Kevin D. Cooper, MD, FAAD, Vice President-elect
April W. Armstrong, MD, MPH, FAAD
Lindy P. Fox, MD, FAAD
Maria K. Hordinsky, MD, FAAD
Jennifer Lucas, MD, FAAD
Tammie C. Ferringer, MD, FAAD
Brad P. Glick, DO, MPH, FAAD
Adrian O. Rodriguez, MD, FAAD
Ruth Ann Vleugels, MD, MPH, FAAD
Bruce A. Brod, MD, MHCI, FAAD
Brent R. Moody, MD, FAAD
Todd Schlesinger, MD, FAAD
Allison T. Vidimos, MD, RPh, FAAD
M. Laurin Council, MD, MBA, FAAD
Carrie L. Davis, MD, FAAD
Amy J. Derick, MD, FAAD
Alexander S. Gross, MD, FAAD
Howard W. Rogers, MD, PhD, FAAD
Dhwani S. Mehta, MD, FAAD, Young Physician Board Advisor
Rebecca Y. Dufner, MD, MBA, Residents-Fellows Board Advisor
Adebola O. Ogunbiyi, MD, IFAAD, International Board Advisor
Elizabeth K. Usher, MBA, Executive Director and CEO
Melanie Hall, Senior Vice President, Marketing and Communications
Krista D. Kauper, JD, Senior Vice President, Strategy & Membership
Karry La Violette, Senior Vice President, Advocacy & Policy
Sarah Tancredi, MBA, PHR, Senior Vice President, Operations
Rudy Anderson, CAE, Vice President, Development and Revenue
Steven Debnar, MBA, Vice President, Finance
Sukhjeet S. Ahuja, MD, MPH, Vice President, Science and Quality
Cindy Kuhn, MSc, Vice President, Membership & Community Impact
Amy Outschoorn, EdD, Vice President, Education & Practice Management
Erik Horn, MBA, Senior Director, Technology & Security
Timothy A. Moses, CMP, Senior Director, Meetings & Conventions,
Katie Domanowski, Senior Director, Communications
Cyndi Del Boccio, Director, Governance
Lara Graf, MS, Director, Medical Journals Publishing
Michelle Pizarro, MHA, Director, Executive Projects & Operations
Robert M. Portman, JD, General Counsel
Jason Z. Qu, JD, General Counsel

Guests

Murad Alam, MD, FAAD, Incoming President-elect
Lawrence J. Green, MD, FAAD, Incoming Vice President-elect
Sabra Sullivan, MD, PhD, FAAD, Incoming Assistant Secretary-Treasurer

**SUMMATION REPORT
AAD BOARD OF DIRECTORS MEETING
MARCH 10, 2025
PAGE 2 OF 11**

Andrew F. Alexis, MD, MPH, FAAD, Incoming Board of Director
A. Shadi Kourosh, MD, MPH, FAAD, Incoming Board of Director
Seth L. Matarasso, MD, FAAD, Incoming Board of Director
Joseph Merola, MD, MSc, FAAD, Incoming Board of Director
Bridget McIlwee, DO, FAAD, Incoming Young Physicians Board Advisor
Fatima Mirza, MD, MPH, Incoming Residents/Fellows Board Advisor
Anne Louise Housholder, MD, FAAD, Chair, Professionalism and Ethics Committee

CALL TO ORDER

Seemal R. Desai, MD, FAAD, President and presiding, called the meeting of the Board of Directors of the American Academy of Dermatology (AAD) to order at 8:06 a.m. (Eastern) on Monday, March 10, 2025.

QUORUM

Daniel D. Bennett, MD, FAAD, Secretary-Treasurer, declared that a quorum was present for the transaction of business.

ORDER OF BUSINESS/INTRODUCTORY MATTERS

Board Obligations and Duties

Dr. Bennett discussed the fiduciary duties of Board members including the duty of care, duty of loyalty, and duty of obedience. He also discussed the importance of antitrust compliance, protection of the organization's assets, including its intellectual property, and confidentiality, including limits on notetaking and the use of AI notetaking or meeting recording tools.

Dr. Bennett then discussed the importance of conflict-of-interest disclosures and noted that the Board members' disclosure of outside interest forms had been posted to BoardEffect. He stated that the Executive Committee had compared the Board's executive summary of disclosures to the agenda topics for the meeting in an effort to preemptively identify potential conflicts or dualities of interest. Dr. Bennett emphasized that this review does not override each Board members' affirmative responsibility to identify and disclose potential conflicts of interest as they arise during the course of the Board's discussions. He noted that the existence of outside interests is common, can be managed effectively through disclosure, and should not be seen in a negative light. Dr. Bennett also reminded Board members to update their disclosure forms on a regular basis. He then asked if the Board members had any additional conflicts to disclose. None were declared.

Parliamentary Procedures and Separate Order of Business

Jason Z. Qu, JD, General Counsel, reminded the Board members that they would be following the American Institute of Parliamentarians *Standard Code of Parliamentary Procedure* (formerly *Sturgis Code of Parliamentary Procedure*) and that it is essential that the Board follow the order of business for the meeting, and to observe other corporate formalities, to ensure that AAD business is conducted separately from AADA business.

The Board recessed the AAD Board meeting and convened in Executive Session at 8:19 a.m. (Eastern).

The Board adjourned the AAD Executive Session at 11:43 a.m. (Eastern) and convened the AADA Board Meeting at 11:44 a.m. (Eastern).

The Board recessed the AADA Board meeting at 12:18 p.m. and reconvened the AAD Board Meeting at 12:39 p.m. (Eastern).

SUMMATION REPORT
AAD BOARD OF DIRECTORS MEETING
MARCH 10, 2025
PAGE 3 OF 11

Dr. Desai noted how grateful and proud he was to serve as AAD/A President and discussed his philosophy on how the Board members should function and interact. He also discussed the importance of Board members observing their fiduciary obligations, including confidentiality and support of Board actions, of reviewing online meeting materials on *BoardEffect*, and of adhering to parliamentary procedure. Dr. Desai then reviewed some additional logistical and procedural points for the meeting before recognizing and welcoming staff and guests to the meeting, including the incoming directors, officers, and advisors in attendance.

Dr. Desai noted that the AAD online ballot was posted and approved on *BoardEffect* and that the following items were pulled for discussion at the AAD meeting from the online ballot:

- Organizational Structure Committee: Expert Resource Groups Policy
- Council on Science and Research: Manuscript - Genitourinary Syndrome of Menopause: An Important Diagnosis for Dermatologists
- Executive Committee: Parliamentary Procedure Administrative Regulation

AAD OFFICER AND DIRECTOR REPORTS

President's Report

Dr. Desai reported on activities, meetings, and other developments since the November Board meeting, including:

- Advocacy and policy successes including work with Midwest Business Group on Health to educate employers, state advocacy related to prior authorization and scope of practice legislation, engagement with FDA around access to patch testing and benzene-related research, advocating for improvements to the MVP (MIPS Value Pathways) framework before Centers for Medicare & Medicaid Services (CMS), and continued advocacy focused on Medicare payment reform, including member engagement in support of H.R. 879, despite Congress' recent failure to avert Medicare reimbursement cuts in its most recent governing funding resolution;
- Attendance by Academy leaders at a number of domestic dermatological meetings to provide AAD updates and at key international meetings to advance the Academy's strategic goal of establishing cross-border educational partnerships;
- Kickoff of the Ad Hoc Task Force on Dermatologic Care for Unhoused Populations service project in February 2025 providing dermatological services to unhoused individuals in Los Angeles, CA;
- Establishment and kickoff of the Ad Hoc Task Force on Outside Legal Services Selection; and
- Establishment of a work group on CLIA (Clinical Laboratory Improvement Amendments of 1988) as a result of recent CMS policy change removing American Board of Dermatology certification from CLIA lab director qualification requirements.

Secretary-Treasurer's Report

Fourth Quarter Financial Report Ending December 31, 2024

Dr. Bennett referred the Board to pp. 13 – 17 of the background materials and presented the Fourth Quarter Financial Report Ending December 31, 2024, and noted that 2025 Q1 figures would be provided to the Board in May. Dr. Bennett stated that 2024 revenue performance was strong, and that the year ended with a net surplus despite an unexpected accounting shortfall of \$1.6M, which arose from certain DataDerm transition-related expenses being funded as a capital expenditure rather than being released to GOF as originally budgeted.

Dr. Bennett noted that strong revenue performance in categories such as meetings and corporate support outweighed a slight decrease in dues revenue against budget. He also noted that careful expense management in categories such as travel and meetings contributed to the year's financial performance and flagged that strong staff engagement survey results may result in higher-than-expected staff retention levels compared to budget. Dr. Bennett also summarized the Academy's investment returns for 2024 and noted that their performance exceeded benchmarks.

**SUMMATION REPORT
AAD BOARD OF DIRECTORS MEETING
MARCH 10, 2025
PAGE 4 OF 11**

Dr. Bennett reminded the Board that its November 2024 meeting was held in Dallas per a Board-approved modification to its meeting policy and was budgeted to cost 20% more than the budgeted cost of the May 2024 Board meeting. Dr. Bennett stated that the cost of the November 2024 meeting came in under this original budget, although the actual cost of the May 2024 meeting ended up significantly below budget. Dr. Bennett recommended that the Board allow the budget process to bring forward potential additional changes to the Board meeting policy going forward.

Executive Director's Report

Elizabeth K. Usher, MBA, Executive Director and CEO, referred the Board to her written report on pp. 18 – 30. Ms. Usher noted that the quarterly report contained excellent content for the Board covering Academy developments since its November 2024 meeting.

Ms. Usher then highlighted strong preliminary results for the March 2025 Annual Meeting including:

- Historically high attendance which exceeded targets across medical, non-medical, and exhibitor categories, with especially strong non-medical and exhibitor attendance;
- Successful launch of new Member Welcome Reception and Faculty Reception events, with 1300 attendees at the Welcome Reception; and
- Revenue at ~\$3.9M over budget.

A proposed motion was made and duly seconded to approve the President's, Secretary-Treasurer's, and Executive Director's reports for information only.

ACTION: APPROVED

Legal Overview of the Diversity, Equity & Inclusion (DEI) Executive Orders

Mr. Qu delivered a presentation to the Board concerning the legal risks associated with "DEI" and other identity-conscious activities in light of recent judicial developments and the issuance of DEI-related Executive Orders. Mr. Qu outlined how existing case law and current litigation trends have increased the legal risk associated with using strict race-based qualifications to limit access to programs, benefits, and/or opportunities within private nonprofit organizations. Mr. Qu described how a recent legal risk assessment confirmed that the Academy's current programs and activities do not employ high-risk, identity-based qualifications and how the Academy is continuing to refine its DEI strategy to advance access to care and to diverse dermatological providers in line with evolving legal trends and risk areas.

AAD STRATEGIC ISSUES

Key Performance Indicator Targets for 2025

Ms. Usher and Krista D. Kauper, JD, Senior Vice President, Strategy & Membership, referred the Board to p. 32 of the background materials and presented the Key Performance Indicator (KPIs) Targets for 2025. Ms. Usher and Ms. Kauper discussed the process for developing and tracking KPIs and described how 2024 results informed 2025 targets for KPIs including Member Satisfaction, Member Retention, Year-Over-Year Revenue Growth, Net Surplus, and Employee Engagement, highlighting strong performance in areas such as employee engagement and continuing efforts to improve membership retention.

A proposed motion was made and duly seconded to approve key performance indicators and Level 1 metrics for 2025 as presented.

ACTION: APPROVED

AAD HEARD FROM THE FIELD

Dr. Desai invited Board members to raise issues of concern they were hearing out in the field that fall

**SUMMATION REPORT
AAD BOARD OF DIRECTORS MEETING
MARCH 10, 2025
PAGE 5 OF 11**

under the purview of the AAD Board. The following issues were discussed:

- Positive feedback from various Board members regarding the 2025 Annual Meeting. Recommendations were made or reported from members to (1) move late-breakers to Friday so that they could be discussed on subsequent days and not conflict with the contents of other presentations; (2) add capacity to present rejected late-breakers in alternative formats; (3) prioritize minimizing conflicts between the subject matter of late-brakers and overlapping sessions or symposia; (4) having an A/V “hotline” for course directors; (5) providing licensed music options for use between sessions; (6) adhering to stricter timelines for plenary session speakers; and (7) including more maps throughout the conference center and hotel.
- Specific positive feedback regarding the new Opening Ceremony program and the utility of using the Opening Ceremony as an opportunity to highlight key activities and the value of Academy membership. The cost of the welcome reception was cited as one reason residents or those with a plus-one chose not to attend or opted for conflicting industry events.
- A recommendation was made to expand the Academy’s firefighter screening program to members of the military by leveraging existing relationships with military dermatologist groups.
- A suggestion to include recognition of the Mentor of the Year in the Stars of the Academy program.
- A request to find alternative providers or online sources for the Basic Science Course that had been cancelled for the 2025 Annual Meeting.
- Interest on the part of international members to have voting rights in AAD/A elections.

AAD UNFINISHED BUSINESS

Workgroup on Board Values

Definitions

Cyndi J. Yag-Howard, MD, FAAD, Vice President, referred the Board to pp. 34 – 35 of the background materials and presented the Workgroup on Board Values report. She reminded the Board that it had revised the title and core definitions of each Board Value at its November meeting and had tasked the Workgroup with adding illustrative examples to each Value in lieu of adopting more extensive definitions. The Board discussed the definitions of each Board Value as presented.

A proposed motion was made and duly seconded to approve the edits to the Board values definitions of “Professionalism” as presented and as further edited below:

PROFESSIONALISM embodies respect, integrity, trust, honesty, confidentiality, transparency, preparedness, accountability, and a steadfast commitment to ethical behavior, prioritizing the organization’s mission and vision above personal interests.

ACTION: APPROVED

A proposed motion was made and duly seconded to approve the edits to the Board values definition of “Unity” as presented and as further edited below:

UNITY is built on a foundation of collaboration, trust, and common goals; it drives positive outcomes and ensures alignment of vision, purpose, and actions across the organization.

ACTION: APPROVED

A proposed motion was made and duly seconded to approve the edits to the Board values definition of “Engagement and a Curious Mindset” as presented and as further edited below:

ENGAGEMENT AND A CURIOUS MINDSET drive innovation and foster growth within the organization.

ACTION: APPROVED

A proposed motion was made and duly seconded to approve the edits to the Board values definition of “Strategic Focus and Discipline” as presented and as further edited below:

STRATEGIC FOCUS AND DISCIPLINE provide the board a decision-making framework that ensures all actions are fiscally responsible and aligned with the organization’s strategic priorities and goals.

ACTION: APPROVED

A proposed motion was made and duly seconded to approve the edits to the Board values definition of “Visionary Leadership” as presented and as further edited below:

VISIONARY LEADERSHIP inspires members and staff to align and actively support the organization’s mission and strategic objectives.

ACTION: APPROVED

The Board discussed the examples of each Board Value as presented. A proposed motion was made and duly seconded to approve the proposed examples for the newly defined Board Values as further edited below.

PROFESSIONALISM

1. Everyone comes to the meeting prepared, having reviewed all their meeting materials prior to arrival.
2. Everyone respects the requisite confidentiality of a high functioning board and does not reveal confidential discussions or votes to non-board members.
3. The board speaks with a unified voice and board members support the final decision of the board.
4. Board members speak to each other with respect and do not belittle, condemn, heckle, chastise, or shame other board members or staff.

UNITY

1. Board members engage in healthy debate, encouraging the expression of diverse opinions in the boardroom while presenting a unified front publicly.
2. Board members express solidarity and mutual respect.
3. The board discusses options to enhance our meetings, respects diverse views, and reaches a consensus, presenting a unified direction to the CEO and staff.

ENGAGEMENT AND A CURIOUS MINDSET

1. Board members are open to new ideas and ways to accomplish goals and address challenges.
2. Board members approach their duties with curiosity and a desire for deeper understanding.
3. Board members intentionally bring issues from the field into the boardroom to increase awareness of new challenges or opportunities.

STRATEGIC FOCUS AND DISCIPLINE

1. Board members resist distractions that steer the organization away accomplishing its strategic goals.

**SUMMATION REPORT
AAD BOARD OF DIRECTORS MEETING
MARCH 10, 2025
PAGE 7 OF 11**

2. Board members, along with staff, consistently evaluate progress toward achieving strategic goals.
3. The board reviews information and makes decisions through the lens of alignment with the Academy's strategic goals.

VISIONARY LEADERSHIP

1. Board members rally support and drive momentum as champions of the organization.
2. Board members are passionate about their role as leaders and role models.
3. Board members lead by example and advocate for the organization's values and vision through both voice and action.
4. Board members accept and seek out opportunities to lead and educate on behalf of the Academy.

ACTION: APPROVED

Executive Committee

Societal Issues Scorecard

Dr. Desai referred the Board to p. 36 of the background materials and noted at its November meeting, the Board of Directors approved piloting the societal issues scorecard and had requested a report back to the Board of Directors on experiences from this pilot in March 2025.

Melanie Hall, Senior Vice President, Marketing and Communications, and Katie Domanowski, Senior Director, Communications, reported that the Executive Committee had utilized the scorecard once during the pilot period in response to a request from Fox News for comment from the Academy on state legislation concerning transgender care for minors. They noted that the average initial score for this request was 18.5, suggesting that leadership might consider selective engagement with this topic. They stated that, following discussion, leadership decided not to make any comment or statement on this topic.

Given the unexpectedly high score received in this pilot case under the original scorecard, the Academy's scorecard consultant was asked to recalibrate the tool to weight the first "relevance to dermatology" question the highest and making a positive response to that question mandatory for proceeding with the scorecard.

Dr. Desai noted that this approach reflected earlier feedback from the Board on the centrality of "relevance to dermatology" within this framework and emphasized that the scorecard was meant to be an assistive tool for leadership, not the sole decider of whether or not the Academy would comment on a topic.

A proposed motion was made and duly seconded to approve the proposed recommendation to adopt an adjusted version of the societal issues scorecard as a decision-making aid when determining whether the Academy should weigh in on societal issues.

ACTION: APPROVED

AAD NEW BUSINESS

Professionalism and Ethics Committee

Social Media Ethics Workgroup

Adrian O. Rodriguez, MD, FAAD, reminded the Board that a Workgroup comprising members of the Professionalism and Ethics Committee, the Council on Communications, and at large members had been convened to address the role of social media within the Academy's ethics process and relevant policies, procedures, and ethics codes.

Dr. Rodriguez reported that the Workgroup had met and drafted recommendations for the Professionalism and Ethics Committee on how the Academy's *Position Statement on Medical Professionalism in the Use of Social Media*, *Board Governance Policy: Conduct at AAD/A Meetings and other AAD/A Activities*, and *Administrative Regulation on Code of Medical Ethics for Dermatologists* could be updated and modernized to ensure that the Academy's oversight of social media activities was correctly aligned with its mission and operational priorities. Dr. Rodriguez stated that the Professionalism and Ethics Committee had voted to approve the recommendations as presented for review by the Board of Directors and noted that the Committee would be presenting a more comprehensive proposal to update the scope of the Academy's ethics process at the May 2025 Board meeting.

After discussion and deliberation, a motion was made and duly seconded to refer the edits from the Social Media Ethics Workgroup back to the Professionalism and Ethics Committee for further consideration and presentation as part of the Committee's May 2025 report on more comprehensive proposed changes to the Academy's ethics process.

ACTION: APPROVED

AAD/A Organizational Structure Committee

Advisory Board – Organizational & Operational Guidelines

Amy J. Derick, MD, FAAD referred the Board to the background materials on pp. 57 – 66 and stated that the Advisory Board was unable to meet its quorum requirement of 50% plus one of constituent society representatives for the 2024 Innovation Academy meeting and that this impeded the Advisory Board's ability to conduct business. Dr. Derick stated that a modification of the quorum requirement from 50% plus one to 33%, along with other organizational changes set forth in the background materials, was being submitted from the Organizational Structure Committee to the Board for consideration and approval.

The Board discussed the proposed change to the Advisory Board quorum requirement. A motion was made and duly seconded to approve the proposed recommendation to revise the *Board Governance Policy – Advisory Board Organizational & Operational Guidelines* as presented, but as further amended so that the Annual Meeting quorum requirement remains at 50% plus one of voting members and the modified 33% plus one quorum requirement applies only to the Innovation Academy meeting.

ACTION: APPROVED

Expert Resource Groups Board Governance Policy

Dr. Bennett referred the Board to the background materials on pp. 120 – 128 and stated that the Organizational Structure Committee was proposing a change to the name of Expert Resource Groups (ERGs) to Special Interest Groups (SIGs) alongside other changes to the governance of the SIGs and to the language of Expert Resource Groups policy language.

A motion was made and duly seconded to approve the revisions to the Board Governance Policy – Expert Resource Groups (ERGs) as presented.

After discussion and deliberation, a motion was made to refer the edits to the *Expert Resource Groups Board Governance Policy* back to Organizational Structure Committee for further discussion with ERG stakeholders.

ACTION: APPROVED

Ad Hoc Nominating Committee

Dhwani S. Mehta, MD, FAAD, Young Physician Board Advisor, was not present for and did not participate in discussion and voting on this agenda item.

Dr. Yag-Howard, Chair, 2025 Ad Hoc Nominating Committee, stated the Ad Hoc Nominating Committee proposed the following two candidates to the Board for election to serve as a Board representative on the Nominating Committee. This year the candidates were from the Midwest/Mid-South region. The nominees were:

Dhwani Mehta, MD, FAAD
Melissa Piliang, MD, FAAD

The Board discussed the two candidates and voted by closed ballot.

Dr. Bennett announced that the new Board representative on the Nominating Committee would be Dr. Piliang.

DataDerm Oversight Committee

Bruce A. Brod, MD, MCHI, FAAD, referred the Board to the background materials on pp. 87 – 88 and provided an update on the DataDerm platform migration process. Dr. Brod stated that existing practices were being successfully migrated to the new platform and that 2024 MIPS reporting was on schedule to be completed through the new platform. He noted that next steps would include the continued integration of new users, continued winding down of the legacy platform, and evaluation of future enhancements.

A proposed motion was made and duly seconded to approve the DataDerm Oversight Committee report as presented for information only.

ACTION: APPROVED

Council on Member Services

2025 – 2027 International Board Advisor Selection

April W. Armstrong, MD, MPH, FAAD, referred the Board to pp. 112 – 116 of the background materials and stated that the Council on Member Services had proposed the following two candidates for the International Board Advisor position:

Baruch H. Kaplan, MD, IFAAD from Israel
Abdul-Ghani M. Kibbi, MD, IFAAD from Lebanon

Dr. Desai reminded the Board that selection of the International Board Advisor was scheduled to occur at the Board's last meeting, but there were concerns regarding whether a new Board-approved process for selecting and vetting candidates had been followed. Ms. Kauper noted that the process had been followed for the selection of these candidates and that the new International Board Advisor would serve from March 2025 until the close of the Annual Meeting in 2027.

The Board discussed the qualifications of the two candidates and voted by closed ballot.

Dr. Bennett announced that the new International Board Advisor would be Dr. Kaplan.

AAD Annual Meeting Future Sites 2031 – 2039

Dr. Bennett referred the Board to pp. 129 – 137 of the background material and stated the Academy's

**SUMMATION REPORT
AAD BOARD OF DIRECTORS MEETING
MARCH 10, 2025
PAGE 10 OF 11**

Meetings & Conventions Department had been working to identify and select locations for future Annual Meetings over the past 12 months, resulting in its proposed recommendations for sites to host the AAD Annual Meeting for years 2031 through 2039.

Dr. Bennett described how the Meetings & Conventions team had completed extensive evaluation of potential sites through a Request for Proposal (RFP) process with a focus on maximizing attendance and generating revenue. Ms. Kauper stated that advanced planning was necessary given the size and complexity of the Annual Meeting and that the site selection criteria included considering the site's location, available dates, available facilities, and the site's historical performance, if applicable.

Timothy A. Moses, CMP, Senior Director, Meetings & Conventions, shared the results of the RFP process and described why past cities like Denver and New Orleans, along with potential new locations like Atlanta, Chicago, Las Vegas, and Houston, were not selected. Mr. Moses described why the team ultimately selected past cities Boston, Orlando, Washington D.C., and San Diego, along with Dallas as a new city for 2032 and 2035, as future sites based on the selection criteria.

A proposed motion was made and duly seconded to approve the dates and locations for the 2031-2039 AAD Annual Meetings.

East	2031	Boston, MA	March 21-25
Central/South	2032	Dallas, TX	March 19-23
West	2033	*San Francisco, CA	March 25-29 <i>*(Previously confirmed in 2018)</i>
East	2034	Orlando, FL	March 17-21
Central/South	2035	Dallas, TX	March 16-20
West	2036	San Diego, CA	March 21-25
East	2037	Washington, DC	March 27-31
Central/South	2038	Orlando, FL	March 26-30
West	2039	San Diego, CA	March 25-29

ACTION: APPROVED

AAD Annual Organizational Resolution

Dr. Bennett referred the Board to page 117 of the background material and stated this resolution was a housekeeping matter that allows the officers and staff to transact business on behalf of the organization.

A proposed motion was made and duly seconded to adopt the AAD Annual Organizational Resolution as presented.

ACTION: APPROVED

Executive Committee

Parliamentary Procedure Administrative Regulation

Dr. Derick referred the Board to pp. 138 – 139 of the background materials and stated that her concerns regarding the proposed edits arose from the practice of using BCCs while conducting CCTF votes via email. Sarah Tancredi, MBA, PHR, Senior Vice President, Operations, clarified that BCC was no longer being used for email voting.

A proposed motion was made and duly seconded to approve the proposed edits to the Parliamentary Procedure Administrative Regulation as presented.

ACTION: APPROVED

AAD CONSENT AGENDA

Executive Committee February 27, 2025 Summation Report

Dr. Bennett referred the Board to p. 140 – 141 of the background materials. A proposed motion was made and duly seconded to approve the February 27, 2025 Executive Committee summation report.

ACTION: APPROVED

Council on Science and Research

Manuscript: Genitourinary Syndrome of Menopause: An Important Diagnosis for Dermatologists

Dr. Brod stated the last column in Table 1 – Dermatology Notes could support misleading conclusions and was proposed to be removed.

Carrie L. Davis, MD, FAAD, stated that she would request that the authors of the Manuscript extract the language below, including the additional proposed edit, from its current location within descriptive text accompanying Table 1 for placement into the body of the manuscript instead.

Table 1. Select topical non-hormonal and hormonal formulations for GSM. Adapted from UpToDate.

*When used as directed, local low-dose VE has minimal side effects and risks due to limited systemic absorption. [Nonetheless, consultation with the patient's oncologist is recommended prior to prescription in cases of estrogen-sensitive cancers.](#) The most common side effects include vaginal discharge, irritation, or itching, as well as vaginal bleeding or spotting, which usually occurs in the first few weeks and should be evaluated if persistent.

A motion was made and duly seconded to approve the additional revisions to the manuscript entitled “Genitourinary Syndrome of Menopause: An Important Diagnosis for Dermatologists” as proposed by Dr. Brod and Dr. Davis.

ACTION: APPROVED

Due to time constraints, the following items were referred to a future Board meeting:

- Revenue Strategy - May 3, 2025 Board meeting
- Council on Science and Research (climate change) – May 3, 2025 Board meeting
- JAAD Publications Committee (open access) – July 12, 2025 Board meeting

ADJOURNMENT

There being no further business, Dr. Desai adjourned the Academy Board of Directors Meeting at 5:08 p.m. (Eastern).

Respectfully Submitted,

Daniel D. Bennett, MD, FAAD
Secretary-Treasurer